To learn more about Dr. Hart and the services she provides please click here:
By Dr. Angelique Hart, MD
Incredibly Effective, Natural Treatment for Your Heart
Want aggressive, natural treatment? Enhanced External Counter Pulsation (EECP) improves circulation to the heart without medications or conventional therapies. We combine Live02 Training (Exercise with Oxygen) with EECP and detoxifying IV Therapies to EECP. These natural therapies help your body heal itself.
Research shows that EECP appears to stimulate the opening of new, natural pathways around narrowed or blocked arteries. Many people who have received EECP treatment report fewer and less severe instances of angina, increased energy levels and have greatly improved their ability to engage in activities of daily living. In addition, patients are often able to enjoy moderate exercise for the first time since they developed angina. No major adverse reactions have been reported.
The following article dated September 9, 2013 was published on PR Newswire – Vasomedical.com
EECP Therapy Receives Class lla Recommendation in European Society of Cardiology Guidelines for the Management of Stable Coronary Artery Disease: New Guidelines Recommended EECP Therapy as a Top Treatment Option for Refractory Angina in its First Inclusion
The IIa classification signifies that the weight of evidence and level of opinion are in favor of a treatment and, in this case, that physicians should consider EECP Therapy as a treatment option for patients suffering from refractory angina.
November (2012), The American College of Cardiology Foundation and The American Heart Association (ACCF/AHA) Task Force on Practice Guidelines issued its new Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease. In this Guideline, EECP Therapy retained the same IIb Class of Recommendation rating it had received in the ACC/AHA 2002 Guideline Update for the Management of Patients with Chronic Stable Angina. The Company has been in active communication with the ACCF/AHA task force, as well as its guideline writing committee, requesting a review of more recent data than was referenced in the 2012 Guideline, for the purpose of upgrading EECP Therapy's level of recommendation to lla in its future guideline.
"It is a breakthrough that EECP Therapy was included in the ESC Guidelines for the first time, and at the same time was given a level IIa recommendation, which means it 'should be considered' as a treatment option as opposed to 'may be considered' recommendation for a IIb rating," said Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc. "We are pleased that the European Society of Cardiology has recognized the value and efficacy of this treatment, as has been demonstrated by many studies. On behalf of all heart patients, we thank the many physicians in the U.S. and Europe who have done great research on EECP Therapy and presented data to ESC for consideration."
"Throughout the past decade, EECP Therapy has been offered to hundreds of thousands of patients in numerous centers and hospitals in the United States and abroad. During this time, we have gathered a wealth of data from many different studies, including randomized controlled trials published in peer-reviewed journals, and have received countless testimonials regarding an improvement to patients' quality of life," continued Dr. Ma. "We believe this treatment option should be made available to a wider patient base. Our responsibility is not only to support and improve this technology, but also to champion the patient who is not receiving this therapy and its benefits. Furthermore, we have a social obligation to support healthcare cost reduction through expanding role of EECP Therapy, which has been demonstrated in clinical literature to reduce re-hospitalizations and emergency room visits. We believe this high recommendation by ESC should help promote a broader acceptance of the EECP Therapy around the world."